(RTTNews) - Silexion Therapeutics Corp. (SLXN), a clinical-stage biotechnology company, announced Tuesday significant preclinical data for SIL-204, its next-generation siRNA therapeutic candidate targeting KRAS-driven cancers.
The findings validate the systemic administration approach, showing robust tumor growth reduction in orthotopic pancreatic cancer models.
This data highlights SIL-204's potential in treating one of the most aggressive cancers, with a 50% reduction in tumor growth observed after 30 days of treatment.
The therapy also demonstrated complete necrosis in about 50% of the tumors in the G12D mutant pancreatic cancer model.
Silexion's new formulation of SIL-204, administered systemically, showed prolonged therapeutic activity with effective drug levels maintained for over 56 days in rat plasma and tissues.
The treatment successfully inhibited key KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D, which are commonly found in pancreatic cancer and other solid tumors.
The company is also investigating the impact of SIL-204 on metastasis in future studies and is optimistic about expanding its treatment strategy for KRAS-driven cancers.
Silexion plans to build on this promising data as it progresses toward clinical development and next-generation treatment strategies.
This development marks a significant milestone in Silexion's commitment to pioneering RNA interference or RNAi therapies for solid tumors, with the potential to offer new treatment options for patients with difficult-to-treat cancers.
Currently, SLXN is trading at $1.14 up by 96.5%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
